Renovia Inc. successfully raised &32.3 million through Series B equity and $10 million through venture debt. Renovia is a company dedicated to come up with diagnostic and treatment products to treat pelvic floor disorders in women. The $42.3 million closed in financing will enable the company to proceed with several new products.
Renovia was well advised by BayCross Capital Group to participate in the Series B financing. The Series B financing was conducted by Perceptive Advisors as well as Ascension Ventures. Many companies participated in the funding drive. The companies includes but not limited to Inova Strategic Investments and Longwood Fund.
In a statement, Marc Beer said that they were thrilled by the support they got from leading investors in the healthcare sector who share the same vision, to diagnose and treat pelvic floor disorder in women. Marc Beer is Renovia’s Co-Founder, Chairman and CEO. He added that the fund drive which saw the participation of more than three leading healthcare investors reckons well with the company’s both clinical and commercial vision.
Marc Beer continued to say that the company is committed to drive more understanding of pelvic floor disorders and build on the body of knowledge which will ultimately lead to reduced healthcare costs in the long-run. He continued to say that the support they are getting indicates that investors believe in the value of products they are developing.
According to a research, urinary incontinence affects 250 million women worldwide. Since the conception of Renovia, the company has been dedicated to develop therapeutic and diagnostic products to improve the lives of women. The company’s Leva device has been approved by FDA and it is designed to ensure efficient movement of the levator plate. The companies full product line leverage technology and value-based data to give cost-effective and precise treatment of the disorder’s symptoms in real-time, while at the same time collecting and recording the progress of the patient’s health.
The senior leadership team of Renovia received a major boost as three executives joined the team.
The company was founded to develop therapeutic and diagnostic products to treat pelvic floor disorders affecting women around the world. Renovia use state-of-the-art technologies that enables it to provide training of pelvic floor muscle movement in real-time while at the same time collecting and recording the progress of the treatment. The company’s efforts are powered by technology and it is committed to provide both scalable and cost-effective care to women around the world.
Marc Beer is a renowned leader in the health industry with over 25 years of experience in development as well as commercialization in devices, biotechnology, pharmaceuticals and diagnostics. He founded Renovia Inc. in 2016 along with Ramon Iglesias. In an effort to fund Renovia’s endeavors, Marc Beer has successfully closed both Series A and Series B round of financing raising $42 million in Series B. He has had a distinguished career so far having worked at Aegerion Pharmaceuticals, founded ViaCell (NASDAQ) and served in various capacities in different companies and boards of directors. Learn more: https://renoviainc.com/leadership/